49 citations
,
May 2018 in “Endocrine” This study found that only eumenorrheic polycystic ovary syndrome patients showed a temporal coupling between kisspeptin and luteinizing hormone pulsatile secretions.
467 citations
,
October 2014 in “European Journal of Endocrinology” This paper reviews the diagnostic criteria, etiological factors, and treatment approaches for PCOS, highlighting the importance of considering metabolic issues such as insulin resistance and obesity, but reports no new findings.
23 citations
,
February 2014 in “Journal of Pediatric and Adolescent Gynecology” This study found that a low-dose intermittent finasteride regimen significantly reduced hirsutism scores in adolescent girls with PCOS or idiopathic hirsutism, with similar efficacy but potentially safer and less expensive than continuous administration.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.
253 citations
,
March 2006 in “The Journal of Clinical Endocrinology and Metabolism” This review discusses the hypothesis that polycystic ovary syndrome may originate in fetal life due to prenatal androgen exposure, but reports no new clinical results.
4025 citations
,
December 2003 in “Human Reproduction” This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.
40 citations
,
January 2003 in “Gynecological Endocrinology” This study found that finasteride significantly reduced hirsutism in women with idiopathic hirsutism or polycystic ovary syndrome over six months, suggesting its potential effectiveness for this condition.
94 citations
,
January 2000 in “The Journal of Clinical Endocrinology and Metabolism” This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.
46 citations
,
January 2000 in “The Journal of Clinical Endocrinology and Metabolism”
113 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.